Slingshot Insights | Once Overview

ONCE Overview

Upcoming Projects (ONCE)

Don’t see a project related to the company you care about? Create your own!

Executed Projects (ONCE)

Don’t see a project related to the company you care about? Create your own!

Expired Projects (ONCE)

An in-depth look at the Gene Therapy Landscape
Tickers: VRTX, BLUE, ONCE, CRSP, EDIT, NTLA
Execute By: Dec 31, 2021
Understanding Spark's LUXTURNA potential in RPE65-mediated IRD blindness currently under review at the FDA
Ticker: ONCE
Execute By: Jan 19, 2018

Upcoming & Overdue Catalysts (ONCE)

Don’t see a catalyst related to the company you care about? Create your own!

Occurred Catalysts (ONCE)

Spark's (ONCE) gene therapy SPK-9001 Phase 1/2 in hemophilia B study data released
Ticker: ONCE
Occurred on: May 22, 2018
LUXTURNA (voretigene neparvovec) gene therapy for the treatment of patients with vision loss due to Leber congenital amaurosis PDUFA date set for Jan. 12, 2018.
Ticker: ONCE
Occurred on: Dec 19, 2017
Advisory Committee Meeting on October 12, 2017 for Spark Therapeutics (ONCE) Voretigene neparvovec (SPK-RPE65) in treating vision loss due to confirmed biallelic RPE65 mutation-associated retinal dystrophy
Ticker: ONCE
Occurred on: Oct 12, 2017
SPK-FIX hemophilia B update expected at ASH 2016
Ticker: ONCE
Occurred on: Dec 04, 2016
Spark Therapeutics Announces Updated Data from First Cohort in Hemophilia B Phase 1/2 Trial Demonstrating Consistent, Sustained Therapeutic Levels of Factor IX Activity
Ticker: ONCE
Occurred on: Jun 13, 2016

Strategic Initiatives (ONCE)

Don’t see a strategic initiative related to the company you care about? Create your own!